FindTrial
Sign In

Comparative efficacy and safety of anti-IL-5 therapies and placebo in patients with uncontrolled eosinophilic asthma: a meta-analysis of phase 3 trials

Comparative efficacy and safety of anti-IL-5 therapies and placebo in patients with uncontrolled eosinophilic asthma: a meta-analysis of phase 3 trials - efficacy and safety of anti-IL-5 therapies

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000026707
Enrollment
1000
Registered
2017-03-27
Start date
2016-12-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uncontrolled asthma

Interventions

None listed

Sponsors

Showa University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: uncontrolled asthma

Exclusion criteria

Exclusion criteria: heavy smoker patients with severe cardiovascular disease

Design outcomes

Primary

MeasureTime frame
rate ratio for asthma exacerbation—

Countries

Japan

Contacts

Public Contactkoichi ando

Showa University Division of Respiratory Medicine and Allergology, Department of Medicine

koichi-a@med.showa-u.ac.jp+81-3784-8532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026